



## **Northern Biologics Announces Global Acquisition of Clinical-Stage Antibody by AstraZeneca**

*Acquisition of MSC-1, an anti-LIF antibody that targets the tumor microenvironment*

**Toronto, Canada – October 2nd, 2020** – Northern Biologics has reached an agreement for the acquisition of the company’s lead asset, MSC-1, by an AstraZeneca subsidiary. MSC-1 is an anti-LIF antibody that has completed Phase 1a clinical studies for the treatment of solid tumors. Deal terms are undisclosed.

MSC-1 was Northern’s sole remaining asset following the May acquisition of preclinical assets by Boehringer Ingelheim.

“This transaction with AstraZeneca can both accelerate and expand the development of MSC-1,” said Philip Vickers, Ph.D., President and CEO of Northern Biologics. “I am pleased that in AstraZeneca we have found a great company to further develop this exciting antibody while also providing a return to our investors.”